脓肿分枝杆菌固有利福霉素耐药由ADP-核糖基转移酶MAB_0591介导
本研究探讨MAB_0591(arrMab)编码的利福平ADP-核糖基转移酶(Arr_Mab)在脓肿分枝杆菌固有高水平利福平耐药中的作用。通过异源表达和基因敲除实验,发现Arr_Mab是脓肿分枝杆菌固有利福霉素耐药的主要决定因素,且C25氨基甲酸酯修饰只能部分克服其耐药性。
要点
- Arr_Mab是脓肿分枝杆菌固有利福霉素耐药的主要决定因素
- C25氨基甲酸酯修饰的利福霉素衍生物仍受Arr_Mab修饰
- MAB_0591异源表达可使大肠杆菌和结核分枝杆菌获得利福平耐药
核心结论
- Arr_Mab是脓肿分枝杆菌固有利福霉素耐药的主要决定因素。
- C25氨基甲酸酯修饰只能部分克服Arr_Mab介导的利福霉素耐药。
研究设计与样本
- 构建表达MAB_0591的重组大肠杆菌和结核分枝杆菌菌株,以及MAB_0591缺失的脓肿分枝杆菌突变株。
- 采用MIC试验研究对利福平和C25氨基甲酸酯修饰的利福霉素衍生物的敏感性。
主要发现
- MAB_0591异源表达使大肠杆菌和结核分枝杆菌对利福平产生耐药。
- 脓肿分枝杆菌ΔarrMab突变株的利福霉素MIC值一致低于亲本菌株ATCC 19977。
- 用arrMab互补后,脓肿分枝杆菌ΔarrMab突变株恢复利福霉素野生型表型。
- C25修饰增加利福霉素对野生型脓肿分枝杆菌的活性。
- 在脓肿分枝杆菌ΔarrMab突变株中的MIC研究表明C25修饰的利福霉素仍受Arr_Mab修饰。
临床怎么用
- 提示Arr_Mab是脓肿分枝杆菌固有利福霉素耐药的关键因素,C25修饰衍生物可能部分有效但耐药仍存在。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Rifampicin, a potent first-line TB drug of the rifamycin group, shows only little activity against the emerging pathogen Mycobacterium abscessus. Reportedly, bacterial resistance to rifampicin is associated with polymorphisms in the target gene rpoB or the presence of enzymes that modify and thereby inactivate rifampicin. The aim of this study was to investigate the role of the MAB_0591 (arrMab)-encoded rifampicin ADP-ribosyltransferase (Arr_Mab) in innate high-level rifampicin resistance in M. abscessus. METHODS: Recombinant Escherichia coli and Mycobacterium tuberculosis strains expressing MAB_0591 were generated, as was an M. abscessus deletion mutant deficient for MAB_0591. MIC assays were used to study susceptibility to rifampicin and C25 carbamate-modified rifamycin derivatives. RESULTS: Heterologous expression of MAB_0591 conferred rifampicin resistance to E. coli and M. tuberculosis Rifamycin MIC values were consistently lower for the M. abscessus ΔarrMab mutant as compared with the M. abscessus ATCC 19977 parental type strain. The rifamycin WT phenotype was restored after complementation of the M. abscessus ΔarrMab mutant with arrMab Further MIC data demonstrated that a C25 modification increases rifamycin activity in WT M. abscessus However, MIC studies in the M. abscessus ΔarrMab mutant suggest that C25 modified rifamycins are still subject to modification by Arr_Mab CONCLUSIONS: Our findings identify Arr_Mab as the major innate rifamycin resistance determinant of M. abscessus. Our data also indicate that Arr_Mab-mediated rifamycin resistance in M. abscessus can only in part be overcome by C25 carbamate modification.
引用
- Rominski A, Roditscheff A, Selchow P, et al. Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591. J Antimicrob Chemother. 2016. PMID: 27999011. doi:10.1093/jac/dkw466
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。